Unknown PHASE1 INTERVENTIONAL 2-arm NCT03271515

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies

Sponsor: Beijing Doing Biomedical Co., Ltd.

Conditions Leukemia Lymphoma

Interventions anti-CD19 anti-CD20 Bispecific CAR-T

Updated 7 times since 2017 Last updated: Jan 19, 2021 Started: Mar 1, 2021 Primary completion: Mar 1, 2022 Completion: Mar 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Leukemia and Lymphoma and is currently ongoing. Beijing Doing Biomedical Co., Ltd. leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Feb 2021 — Apr 2023 [monthly]

Not Yet Recruiting PHASE1

Status: Unknown Status → Not Yet Recruiting
Jan 2021 — Feb 2021 [monthly]

Unknown Status PHASE1

▶ Show 2 earlier versions

May 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Oct 2017 — May 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Doing Biomedical Co., Ltd.

Data source: Beijing Doing Biomedical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sanhe, China